Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)

NCT05118789 is registered in ClinicalTrials.gov with Nuvalent Inc. as lead sponsor.

NCT NCT05118789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05118789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)
Lead sponsor
Nuvalent Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 4, 2022
Completion date
December 31, 2028
Enrollment
359 (estimated)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced solid tumor, metastatic solid tumor